Key players in the Clostridium difficile infection (CDI) market include Merck & Co., Tillotts Pharma, Astellas Pharma, Pfizer, Vedanta Biosciences, MGB Biopharma, Crestone, Inc., ImmuniMed Inc., Ferring Pharmaceuticals, Deinove, Lumen Bioscience, Inc., Hospices Civils de Lyon, Wake Forest University, and others.
The CDI market is projected to grow significantly due to increasing prevalence of the disease and rising awareness. Additionally, the introduction of multi-stage pipeline products is expected to have a significant impact on market trends during the forecast period.
DelveInsight's Clostridium difficile Infection Market Insights, Epidemiology, and Market Forecasts - 2034 provides an in-depth analysis of CDI covering historical and projected epidemiology and market trends in the US, EU5 (Germany, Spain, Italy, France, UK), and Japan.
The report includes insights on emerging drugs, current treatments, market share of treatments, and projected market size from 2020 to 2034. We also assess current treatment algorithms, market drivers and barriers, and unmet medical needs to identify potential opportunities.
Click here to know more about Clostridium difficile infection market outlook, drug uptake, treatment scenarios, and epidemiological trends. Clostridium difficile infection market forecast
Key highlights of the Clostridium difficile market report:
- The CDI market was valued at approximately USD 540 million in 2023 and is expected to grow at a significant CAGR from 2020 to 2034.
- In May 2024, Vedanta Biosciences announced the first patient dosing in the Phase 3 RESTORATiVE303 international clinical trial of VE303, which is intended to form the basis of a Biologics License Application (BLA) submission to the FDA.
- Approved CDI treatments include Merck's DIFICID (fidaxomicin) and ZINPLAVA (bezloxumab). Although these treatments offer improved cure rates, they face the challenge of high cost and limited availability on the market.
- Several companies are actively investing in research and development of new treatments, with prominent pipeline candidates including PF-06425090 (Pfizer's vaccine), CP101 (Finch Therapeutics), VE303 (Vedanta Biosciences), and MGB-BP-3 (MGB Biopharma). These treatments are expected to be launched between 2024 and 2034.
- The number of CDI cases in the 7MM in 2023 is estimated to be approximately 670,000, and is projected to increase by 2034, mainly due to an aging population that is more susceptible to infectious diseases.
- The highest incidence of CDI was in those 65 and older, followed by the 18-64 age group.
Get Free Sample of Clostridium difficile Infection Market Report -
Key players in the Clostridium difficile market
- Merck & Co.
- Tillots Pharma
- Astellas Pharma
- Pfizer
- Vedanta Bioscience
- MGB Biopharma
- Crestone Co., Ltd.
- Immunimed Co., Ltd.
- Ferring Pharmaceuticals
- Deinove
- Lumen Bioscience Co., Ltd.
- Civil Hospice of Lyon
- Wake Forest University
Main treatments for Clostridium difficile infection
- ZINPLAVA (bezloxumab) – Merck Sharp & Dohme
- DIFICID / DIFICLIR / DAFCLIR (fidaxomicin) – Merck & Co / Tillotts Pharma / Astellas Pharma
- PF-06425090 (CDI vaccine) – Pfizer
- VE303 – Vedanta Bioscience
- MGB-BP-3 – MGB Biopharma
- CRS3123 – Crestone Co., Ltd.
- IM-01 – ImmuniMed Inc.
- RBX2660 – Ferring Pharmaceuticals
- DNV3837 – Deinobe
- LMN-201 – Lumen Bioscience, Inc.
- EXL01 – Lyon Civic Hospice
- Ormadacycline Injection – Wake Forest University
Download the report to understand the factors driving epidemiological trends in Clostridium difficile infections. Epidemiological insights into Clostridium difficile infections
Overview of Clostridium difficile infection
Clostridium difficile infection (CDI) is caused by the bacterium Clostridium difficile (C. diff) and primarily affects the colon, causing symptoms ranging from mild diarrhea to life-threatening colitis.
Epidemiology of Clostridium difficile infection
The epidemiology section provides a detailed analysis of past, present and future trends in CDI in the 7MM (2020-2034). This section identifies key drivers of epidemiological trends and analyzes diagnosed patient populations by reviewing various studies and expert insights.
Epidemiological segmentation of Clostridium difficile infections
- Total prevalence of CDI
- Prevalent CDI cases by severity
- Gender-specific CDI prevalence
- Cases diagnosed with episodic and chronic CDI
Drug intake and pipeline for Clostridium difficile infection
The drug uptake section provides insight into the adoption rates of recently launched and upcoming treatments. Covers CDI market uptake by drug, patient adoption by therapy, and drug sales performance.
Additionally, treatment evaluations identify the fastest growing treatments and factors that contribute to their success. This section also provides a comparative analysis of market share.
This report further examines the state of CDI pipeline development, highlighting key clinical-stage candidates, company collaborations, acquisitions, and regulatory advances.
Clostridium difficile market drivers
- Advances in novel CDI therapies
- Increased demand for effective antibiotics
- New technologies enable improved disease management
To learn more about treating Clostridium difficile infections, please visit @. Drugs to treat Clostridium difficile infection
Clostridium difficile infection market opportunity
There is still a significant need for treatments that restore the gut microbiome and prevent the recurrence of infections. Companies that successfully develop such treatments could gain a significant competitive advantage.
Scope of the Clostridium difficile Infection Market Report
- Research period: 2020 to 2034
- Geographic coverage: 7MM (US, EU5, and Japan)
- Major CDI companies: Merck & Co, Tillotts Pharma, Astellas Pharma, Pfizer, Vedanta Biosciences, etc.
- Major CDI treatments: ZINPLAVA, DIFICID, PF-06425090, VE303, MGB-BP-3, etc.
- CDI Market Analysis: Market Drivers, Barriers, Competitive Environment, Unmet Needs
- Market Intelligence: SWOT Analysis, PESTLE, Porter's Five Forces, BCG Matrix
Discover the future of CDI treatment @ Treatment of Clostridium difficile infection
table of contents
- Clostridium difficile Infection Market Report Overview
- Summary of Clostridium difficile infection
- SWOT analysis of Clostridium difficile infection
- Overview of patient proportion (%) with Clostridium difficile infection
- Clostridium difficile market overview
- Background and overview of Clostridium difficile infection
- Epidemiology and patient numbers of Clostridium difficile infection
- Number of Clostridium difficile infections by country
- Current treatments and medical practices for Clostridium difficile infection
- Unmet needs in Clostridium difficile infections
- New treatment for Clostridium difficile infection
- Clostridium difficile infection market outlook
- Clostridium difficile Infection Market Analysis by Countries (2020-2034)
- Market Access and Treatment Reimbursement for Clostridium difficile Infections
- Clostridium difficile infections market drivers
- Clostridium difficile Infection Market Barriers
- Clostridium difficile appendix infection
- How to report Clostridium difficile infection
- DelveInsight Features
- Disclaimer
- About DelveInsight
About DelveInsight
DelveInsight is a leading healthcare business consultant and market research firm specializing in life sciences. We support pharmaceutical companies by providing comprehensive end-to-end solutions to improve their performance.
We also provide healthcare consulting services that accelerate business growth with the benefit of market analysis and overcome challenges with a practical approach.
Contact information:
Himanshu
hmason@delveinsight.com
info@delveinsight.com
+14699457679
French
Dutch